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Endovascular aortic repair (EVAR) treatment for ruptured aortoiliac aneurysms (rAIA) avoids the additional surgical
insult to physiology that comes with laparotomy and open repair (OR). In systematic reviews, the pooled mortality rate
from rAIA after EVAR is around 20% and morbidity around 40%. The proportion of patients with rAIA treated by EVAR
is steadily increasing, as most centers are adopting an EVAR as a first line therapy. However, two trials, one randomized
(n 32) and one nonrandomized, failed to demonstrate any benefit of EVAR to OR. The multicentric randomized study
named ECAR (for Endosvasculaire vs Chirurgie dans les Anévrysmes Rompus) was setup on 160 patients to compare the
EVAR vs OR in rAIA. The primary outcome is mortality at 1 month. The study started in January 2008 and is still in
progress. ( J Vasc Surg 2010;51:267-70.)In patients with ruptured aortoiliac aneurysms (rAIA),
endovascular aneurysm repair (EVAR) is now considered a
good alternative to open repair (OR), with 30-day mortal-
ity rates approaching 20% and 50%, respectively.1,2 How-
ever, when the high level of publication bias is taken into
account, the data do not rule out higher mortality rates
after EVAR compared to OR. EVAR would be expected to
yield lower mortality rates because patients with hemody-
namic instability and, therefore, a higher risk of postoper-
ative complications are routinely managed with OR.3 Sim-
ilarly, OR is used routinely in patients with difficult aortic
neck morphologies (short and/or conical shape), which are
also associated with postoperative complications. Never-
theless, the only randomized controlled trial in highly
selected patients with rAIA and stable hemodynamics
found no difference in mortality rates between EVAR and
OR (53% vs 53%, respectively).4 Confusing results were
obtained from the nonrandomized New ERA study (new
endograft treatment in ruptured abdominal aortic aneu-
rysm) comparing EVAR used whenever allowed by the
clinical condition and anatomic configuration to OR oth-
erwise. The 30-day mortality rate was 35% with EVAR and
39% with OR, a nonsignificant difference.5
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doi:10.1016/j.jvs.2009.10.128With the purpose of collecting high-level evidence on
the potential superiority of either EVAR or OR, we de-
Table I. Inclusion and exclusion criteria of the
Endovasculaire vs Chirurgie dans les Anévrysmes Rompus
(ECAR) study
Inclusion criteria:
- Age 18-years-old.
- Ruptured AIA diagnosed by abdominal CT with injection.
- AIA developed on the native abdominal infrarenal aorta or
iliac arteries.
- Stable hemodynamic state: systolic blood pressure of the
patient higher than 80 mm Hg in the absence of continuous
filling and administration of high doses of catecholamines.
Anatomic criteria:
- Length of proximal aortic neck 10 mm.
- Diameter of proximal aortic neck 32 mm.
- Angulation of proximal aortic neck 90°.
- Iliac arteries without severe narrowing or tortuosity.
- Operator with prerequisite of 15 endovascular treatments for
AAAs.
- Hardware for endovascular procedure in the operating room.
Noninclusion criteria:
- Hemodynamic instability.
- Anatomic criteria of noninclusion.
- Asymptomatic aneurysms.
- Symptomatic but not ruptured aneurysms: painful or embolic.
- Mycotic aneurysms.
- False aneurysms.
- Post-EVAR ruptured aneurysm.
- Post-traumatic aneurysm.
- Suprarenal, thoracoabdominal aneurysms.
- Inability to obtain an abdominal CT.
- Patients are not affiliated to social security and protected
persons.
- Pregnant and lactating women.
CT, Computed tomography; AIA, aortoiliac aneurysms; AAA, abdominal
aortic aneurysm.signed a multicenter randomized study called ECAR (En-
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[Endovascular repair vs surgery for ruptured aortoiliac an-
eurysms]).
RATIONALE FOR THE ECAR STUDY
A valid comparison of the clinical effectiveness and
safety of EVAR and OR in patients with rAIA requires both
a uniform study population and strictly controlled experi-
mental conditions. Patients must meet two main inclusion
criteria, namely hemodynamic stability and availability of a
computed tomography (CT) angiogram showing both the
aortic rupture and a favorable neck anatomy. We expect to
find that EVAR is associated with significantly lower mor-
tality rates than OR, and with lower morbidity rates.
STUDY ORGANIZATION
ECAR is a prospective multicenter randomized con-
trolled trial. We will include consecutive patients with rAIA
who present at any of 14 study centers and who are eligible
for treatment with either EVAR or OR.
The main participants of the 14 study centers are the
following: P. Desgranges, H. Kobeiter, J. Marty (principal
investigators), Créteil – Paris XII; Y. Castier, G. Lesèche
Bichat – Paris; J.P. Favre, J.N. Albertini, Saint-Etienne;
P. Gouny, A. Badra, Brest; Y. Alimi, M. Bouffi, Nord-
Marseille; P. Piquet, J.M. Bartoli, La Timone – Marseille; S.
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STUDY OBJECTIVES
The primary objective is to compare 30-day mortality
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Table II. Main variables evaluated in the Endovasculaire
vs Chirurgie dans les Anévrysmes Rompus (ECAR) study
1. Hardman score.
2. The general scoring systems currently available to assess fac-
tors prognosis in patients of intensive care (SAPS, IGS2)
that are highly specific (able to predict survival to 90%).
3. Troponin I on arrival at 8 hours (tolerance of 6-12 hours)
and at 24 hours (tolerance of 24-30 hours) after the inter-
vention.
4. Creatinine and creatinine clearance at 48 hours and at day 30.
5. Intra-bladder pressure: pressure above 20 mm Hg means an
abdominal compartment syndrome.
6. Number of total blood transfusions in total at day 30.
7. Total number of hours of total ventilation including surgery.
8. Abdominal CT scan in the first 48 hours after insertion of
endoprosthesis and at day 30.
9. Length of stay in intensive care.
10. Colonoscopy within the first 48 hours.
SAPS, Simplified Acute Pathology Score; IGS2, Indice de Gravite’ Simplifie’;
CT, computed tomography.st-enha
l CT-sc
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of cardiovascular, pulmonary, gastrointestinal, renal, neu-
rologic morbidity, time spent in the intensive care unit
(ICU), and volume of blood transfusions.
DESIGN
Obtaining informed consent from the patient or next of
kin is difficult in life-threatening emergencies such as rAIA,
but French law allows deferred consent in this situation.
The randomization unit will be the week spent in each
center. Patients presenting during the first week and sub-
sequent odd-numbered weeks will be managed with OR,
and those presenting during the second week and subse-
quent even-numbered weeks with EVAR. The OR and
EVAR weeks will coincide in the 14 study centers. The
beginning of the first week will be defined as the day the
first center opens for the study. This methodology facili-
tates emergency team planning.
PATIENT SELECTION: INCLUSION AND
EXCLUSION CRITERIA
Inclusion criteria are as follows: rAIA documented by
CT angiography, stable hemodynamics, favorable anat-
omy, and availability of an experienced operator and appro-
priate equipment for performing EVAR or OR.
During the study period, each center will enroll con-
secutive patients meeting the inclusion criteria. Ruptured
aneurysm is defined as the presence of blood outside the
wall of an aortoiliac aneurysm on CT scans with and with-
out contrast agent injection. CT findings may consist of a
retroperitoneal hematoma with periaortic blood that may
extend into the perirenal space, pararenal space, or both; or
of an intraperitoneal hematoma. Discontinuity of the aortic
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Fig 2. Monitoring curve of the inclusions of study
(ECAR).wall or a focal gap in otherwise continuous circumferentialwall calcifications may point to the rupture site. Patients
with arteriovenous fistula formation to the vena cava/iliac
vein or to the gastrointestinal tract lumen will be eligible. In
contrast, we will not include patients with contained or
impending rupture (eg, bleeding into a mural thrombus).
To be included, patients will have to be hemodynami-
cally stable, a condition defined as systolic blood pressure
higher than 80 mm Hg at arrival, in the absence of contin-
uous fluid replacement and high-dose catecholamines. An
operator having performed at least 15 EVAR procedures
for abdominal aortic aneurysms will have to be available,
and an operating suite fully equipped for endovascular
intervention. Inclusion and noninclusion criteria are listed
in Table I. Selection of patients with rAIA to the study is
shown in Fig 1.
FOLLOW-UP AND ADVERSE EVENTS
Clinical variables, laboratory tests, and imaging stud-
ies will be evaluated for the study 48 hours and 30 days
after the procedure. The main study variables are listed in
Table II.
STATISTICAL ASPECTS
The sample size for this superiority study was estimated
based on the primary efficacy criterion, that is, 30-day
mortality. We hypothesized that EVAR would be associ-
ated with an at least 20% decrease in 30-day mortality
compared to OR. In patients with rAIA meeting the study
criteria (stable hemodynamics and eligibility for either OR
or EVAR), data from the literature indicate that 30-day
mortality is about 40%. To achieve greater than 80% power
with the alpha risk set at 5%, 80 patients were required in
each treatment group. The number of patients lost to
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statistical analyses will be carried out under the responsibil-
ity of Dr P. Maison with the Créteil clinical research unit.
CURRENT STATUS
The ECAR protocol was approved by the appropriate
ethics committee (Comité Consultatif pour la Protection
des Personnes se prêtant à la Recherche Biomédicale-Ile de
France IX) in July 2007. It is registered at ClinicalTrials.
gov under the identifier NCT00577616. A 120,000 €
grant was obtained from the French Ministry of Health
under the publicly-funded, hospital-based, clinical research
program (Programme Hospitalier de Recherche Clinique)
in 2006 and was transferred to the clinical research unit at
the clinical research and development department (Dépar-
tement de la Recherche Clinique et du Développement).
This grant is not sufficient to pay for the endoprostheses,
which are purchased by each of the 14 study centers, all of
which are public hospitals.
The study started on January 7, 2008 and by the end of
September 2009 45 patients had been included, that is,
28% of the planned study population (Fig 2). One patient
was wrongly included and was further retrieved and 43
patients have completed the 30-day evaluation.
Results on mortality/morbidity are not yet available as
the study is ongoing and does not involve interim analyses.
An independent monitoring committee evaluates the seri-
ous adverse events at regular intervals. No imbalance in
serious adverse events between the two arms has been
found, and the committee has not issued any recommen-
dation to stop the study.
A few general results are of interest. Among all patients
presenting at seven of the study centers with rAIA, about
aneurysm patients, one whose hemodynamic stability and anatomy50% were eligible for the study (range, 35% to 63%). More
than 90% of patients had a CT scan available at arrival at the
hospital (done outside the hospital).
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Aneurysm rupture is often fatal as a result of the combination
of hemorrhagic shock and the subsequent ischemia-reperfusion
injury necessitated by surgical repair. The duration of the former
can be shortened by prompt attention and repair, while the extent
of the latter can presumably be limited by adopting an endovascu-
lar approach. This may seem intuitive to many, but outside of
single center reports an endovascular survival advantage has been
difficult to confirm.
Several ongoing randomized studies are reviewing this further.
These include the Endovasculaire vs Chirurgie dans les Anéurysmes
Rompus (ECAR) and Immediate Management of the Patient with
Rupture: Open Versus Endovascular (IMPROVE) repair studies. At
first glance, these may appear similar, but in reality very different
questions are being asked. ECAR participants comprise a subset of
ruptured aneurysm patients, those with computed tomography (CT)
documented rupture, and specific aortic anatomy (including an infra-
renal neck longer than 10 mm and smaller than 32 mm diameter), and
hemodynamic stability. Once identified, these patients are allocated to
receive open or endovascular repair in weekly blocks. The trial inves-
tigators expect a 20% reduction in early mortality after endovascular
repair and plan to recruit a total of 160 patients (80 to each group).
The ECAR study represents a very specific subgroup of rupturedwould generally predict lower mortality rates than others. As a result,
an endovascular approach may not achieve a statistically significant
reduction in early mortality in this patient group, although improve-
ments in other measures including hospital stay and quality of life may
be observed.
The larger IMPROVE trial in the United Kingdom plans to
recruit 600 patients with ruptured aneurysms to be randomized
to open or endovascular approach. Compared to ECAR, the
IMPROVE trial will attempt to compare an endovascular repair first
to an open repair first strategy. Non-moribund patients with varying
degrees of hemodynamic stability will be randomized to the endovas-
cular or open arm once a clinical diagnosis is made. It is only then that
those randomized to the endovascular arm will undergo CT scanning
to determine anatomic suitability, as determine by the surgeon, and
then will undergo an endovascular or open repair.
Results from both studies are eagerly anticipated, but it is
important to remember that they look at very different questions.
ECAR compares endovascular and open repair in a stable group of
patients with specific anatomy, while IMPROVE compares endo-
vascular and open strategies in a more anatomically and hemody-
namically heterogeneous group. Both studies are important, but
the IMPROVE findings could prove more generalizable to the
entire population of ruptured aneurysm patients.
